摘要
阿戈美拉汀(商品名:Valdoxan),化学名为N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺,是瑟维尔公司研发的第一个褪黑激素类抗抑郁药。由于其兼具褪黑激素受体激动剂活性和5-HT2c受体拮抗剂的活性,从而可有效地治疗抑郁症和改善睡眠参数。鉴于阿戈美拉汀巨大的市场前景,本文对相关的合成工艺类专利文献进行了归纳,以期为国内的医药研发人员提供一定的参考。
Agomelatine(Product Name: Valdoxan), whose chemical name is N-[2-(7-Methoxy-1-naphthalenyl)ethyl]acetamide, is the first melatonergic antidepressant developed by Servier company. It is effective in the treatment of depression and can improve sleep parameters because it is both an agonist of melatoninergic receptor and an antagonist of the 5-HT2 c receptor. In view of the broad market prospects for agomelatine, the related patent documents of agomelatine’s preparation technology have been summarized, in order to provide some reference for domestic pharmaceutical R & D person.
作者
岳国亮
杨莹
Yue Guoliang;Yang Ying(Patent Examination Coorperation Jiangsu Center of The Patent Office,CNIPA,Suzhou 215163,China)
出处
《广东化工》
CAS
2019年第4期113-115,90,共4页
Guangdong Chemical Industry
关键词
阿戈美拉汀
维度新
抗抑郁
合成
agomelatine
valdoxan
antidepressant
synthesis
